$1095 | Single User
$2675 | Global License

Multiple Myeloma: Update Bulletin #2
[Report Updated: 01-12-2017]

Published by FirstWord Pharma: 01 Dec 2017 | 197052 | In Stock
Related Topics: FDA

Introduction



This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of top-line results of the Phase III A.R.R.O.W. trial for carfilzomib (Kyprolis) administered once-weekly at the 70 mg/m2 dose with dexamethasone in rrMM patients; FDA’s partial clinical hold suspending patient recruitment in three studies of BMS’ nivolumab (Opdivo)-based combinations in rrMM: CheckMate-602, CheckMate-039 and CA204142; and BioLineRx’s regulatory filings tolaunch the Phase III GENESIS trial for BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in MM patients

Business Questions:

How do experts view Amgen’s top-line results for the Phase III A.R.R.O.W. trial?

How do KOLs view the results for the higher dose carfilzomib (Kyprolis) and will it impact prescribing of bortezomib (Velcade) and ixazomib (Ninlaro)?

What do experts say about potential increase in cardiovascular complications with the higher dose carfilzomib?

How do experts view the clinical hold on CheckMate-602, CheckMate-039 and CA204142?

Is there a future for PD-1/PD-L1-based combinations in multiple myeloma?

What do experts expect from BioLineRx’s Phase III GENESIS trial for BL-8040?

How do KOLs perceive BL-8040 potential for the mobilization of hematopoietic stem cells for autologous transplantation in patients?

Could BL-8040 replace Sanofi’s plerixafor (Mozobil) and become the new standard of care?

Table of Contents
for Multiple Myeloma: Update Bulletin #2 [Report Updated: 01-12-2017]

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

197052 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Multiple Myeloma: Update Bulletin #2 [Report Updated: 01-12-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...